The EC approved an expanded label for Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) to include treatment of advanced HER2-positive stomach cancer. The humanized mAb against human EGFR-2 ( HER2) is already approved for HER2-positive breast cancer. ...
